

1 **Electrospun pH-sensitive core-shell polymer nanocomposites**
2 **fabricated using a tri-axial process**

3 Chen Yang ^a, Deng-Guang Yu ^{a,*}, Deng Pan ^a, Xin-Kuan Liu ^a, Xia Wang ^a,
4 S.W. Annie Bligh ^b, Gareth R. Williams ^{c,*}

5
6 ^a School of Materials Science & Engineering, University of Shanghai for Science and Technology,
7 516 Jungong Road, Shanghai 200093, China.

8 ^b Faculty of Science and Technology, University of Westminster, 115 New Cavendish Street,
9 London W1W 6UW, UK.

10 ^c UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N
11 1AX, UK.

12
13
14
15
16
17
18

19 *** Corresponding authors:**
20 Prof. Deng-Guang Yu and Dr. Gareth R. Williams

21
22 **Addresses:**

23 **DGY:**
24 School of Materials Science & Engineering,
25 University of Shanghai for Science and Technology,
26 516 Jungong Road, Yangpu District,
27 Shanghai 200093, P.R. China

28 **Tel:** +86-21-55270632
29 **Fax:** +86-21-55270632
30 **Email:** ydg017@usst.edu.cn

31
32 **GRW:**

33 UCL School of Pharmacy
34 University College London
35 29-39 Brunswick Square
36 London
37 WC1N 1AX

38 **Tel:** +44 207 753 5868
39 **Email:** g.williams@ucl.ac.uk

40

41 **Abstract:**

42 A modified tri-axial electrospinning process was developed for the generation of a
43 new type of pH-sensitive polymer/lipid nanocomposite. The systems produced are
44 able to promote both dissolution and permeation of a model poorly water-soluble drug.
45 First, we show that it is possible to run a tri-axial process with only one of the three
46 fluids being electrospinnable. Using an electrospinnable middle fluid of Eudragit
47 S100 (ES100) with pure ethanol as the outer solvent and an unspinnable
48 lecithin-diclofenac sodium (PL-DS) core solution, nanofibers with linear morphology
49 and clear core/shell structures can be fabricated continuously and smoothly. X-ray
50 diffraction proved that these nanofibers are structural nanocomposites with the drug
51 present in an amorphous state. *In vitro* dissolution tests demonstrated that the
52 formulations could preclude release in acidic conditions, and that the drug was
53 released from the fibers in two successive steps at neutral pH. The first step is the
54 dissolution of the shell ES100 and the conversion of the core PL-DS into sub-micron
55 sized particles. This frees some DS into solution, and later the remaining DS is
56 gradually released from the PL-DS particles through diffusion. *Ex vivo* permeation
57 results showed that the composite nanofibers give a more than two-fold uplift in the
58 amount of DS passing through the colonic membrane as compared to pure DS; 74%
59 of the transmitted drug was in the form of PL-DS particles. The new tri-axial
60 electrospinning process developed in this work provides a platform to fabricate
61 structural nanomaterials, and the core-shell polymer-PL nanocomposites we have
62 produced have significant potential applications for oral colon-targeted drug delivery.

63 **Keywords:** Tri-axial electrospinning; core-sheath fibers; polymer-lipid
64 nanocomposites; colon-targeted drug delivery; electrospinnability

65

66

67

68

69

70 **1. Introduction**

71 The fabrication of advanced drug delivery systems (DDSs) is increasingly
72 dependent on the creation of complex architectures and understanding
73 structure-activity relationships at the nanoscale [1-3]. To this end, core-shell
74 nanostructures have been very widely studied in the production of functional
75 nanomaterials, including those for biomedical applications [4-6]. For drug delivery
76 and controlled release, both the core and shell can be loaded with an active
77 pharmaceutical ingredient (API) and/or with different types of pharmaceutical
78 excipients. Applications of such systems include improving the solubility of poorly
79 water-soluble drugs, controlled release of multiple APIs from a single dosage form, or
80 tunable multiple phase release [7-9].

81 Over recent years, polymers and lipids have been the most widely used
82 pharmaceutical excipients, and these materials have acted as the basis for a broad
83 gamut of novel DDSs, being exploited to alter the biopharmaceutical and
84 pharmacokinetic properties of the drug molecule for favorable clinical outcomes
85 [3,10,11]. Numerous core-shell polymeric nanoparticles (NPs) and lipid-based DDS
86 (such as solid lipid dispersions and liposomes) have been investigated for drug
87 delivery through varied administration routes [12-15]. Novel strategies derived from
88 the combined usage of polymers and phospholipids (PLs) have been reported for
89 some biomedical applications (including controlled release) and are presently of
90 intense interest in the pharmaceuticals field. However, virtually all the reported
91 polymer-lipid composites are in the form of microparticles or NPs [4,8,16-18].

92 Core-shell nanofiber-based DDS have received relatively little attention, and to the
93 best of our knowledge there are no reports of drug-loaded polymer-lipid nanofibers
94 being used in drug delivery.

95 Electrospun nanofibers, comprising an API loaded into a filament-forming
96 polymer, have been the focus of much research. They are prepared from a
97 co-dissolving solution of a drug and polymer; this is ejected from a syringe with
98 electrical energy used to rapidly evaporate the solvent and yield one-dimensional
99 fibers with diameters frequently on the nanoscale. This technique is scalable, and
100 several recent reports address large scale fabrication and the potential for commercial
101 products [19-22]. The intense research effort invested in these materials thus appears
102 to be about to yield products which can make a major difference to patients' lives.
103 Electrospinning is a facile, one-step procedure, and the products form as a visible and
104 flexible mat which can easily be recovered from the collector without significant loss
105 of material or damage. The nanofibers produced can further be used as templates to
106 manipulate molecular self-assembly to create drug-loaded NPs or liposomes; the
107 electrospinning technique thus provides not only a bridge between fiber-based and
108 NP-based DDSs, but also between solid and liquid dosage forms [23-26].

109 The most simple, single-fluid, electrospinning process has been explored for
110 approaching two decades, and the applications of the resultant monolithic nanofibers
111 have been probed in a wide range of fields. Current developments in electrospinning
112 are focused in two key areas. The first is the manufacture of electrospun nanofibers on
113 an industrial scale [27-29]. The second line of research involves developing advanced

114 electrospinning techniques to yield nanofibers with sophisticated structural
115 characteristics (such as multiple-compartment nanofibers, core-shell nanofibers, or
116 structured fibers with varied distributions of the API), which in turn impart tunable
117 and multiple functionalities [30-32]. Because of the popularity of core-shell
118 nanostructures and the relative ease of the process, coaxial electrospinning (in which
119 two needles, one nested inside another, are used to handle two working fluids) has
120 been the focus of much research. Other advanced approaches such as side-by-side
121 electrospinning (to yield Janus fibers), tri-axial electrospinning (giving three-layer
122 composites), and other types of multiple-fluid electrospinning have been neglected in
123 comparison [6,9,33].

124 Compared with single-fluid electrospinning, the standard coaxial experiment has
125 greatly expanded the range of fibers which can be produced. These include not only
126 core-shell fibers [34,35], but also fibers prepared from materials without
127 filament-forming properties [36] and used as templates for creating nanotubes (from
128 the fiber as a whole) or the “bottom-up” generation of NPs (self-assembled from the
129 components loaded in the fibers) [26, 37]. For biomedical applications, core-shell
130 nanofibers proffer a series of new possibilities; for instance, it is possible to protect a
131 fragile active ingredient such as a protein from the stresses of the electrospinning
132 processes by confining it to the core, or to vary the APIs concentration in the core and
133 shell to achieve complex drug release profiles [38-41]. In the traditional coaxial
134 process the sheath working fluid must be electrospinnable, but a modified process in
135 which one can utilize unspinnable liquids as the sheath fluid is also possible. The

136 number of polymers which can be directly electrospun is rather limited, but there are
137 numerous unspinnable liquids, and the modified coaxial process should hence further
138 expand the range of functional nanofibers which can be produced [38,42,43].

139 The above discussion is focused on the simultaneous processing of two fluids;
140 working with three or even four fluids simultaneously is also possible, however
141 [44-49]. For example, Han and Steckl reported tri-layer nanofibers for biphasic
142 controlled release, using dyes as model active ingredients [49]. In very recent work,
143 we successfully developed a tri-axial electrospinning process to generate nanofibers
144 with a gradient distribution of the API, allowing us to achieve zero-order drug release
145 profiles [31]. However, in all the tri-axial electrospinning processes reported to date,
146 the three working fluids are all electrospinnable. This limits the applications of the
147 process. If unspinnable liquids can be processed in combination with spinnable
148 working solutions, a much broader selection of functional products could be designed
149 and generated.

150 Building on our previous work developing modified coaxial [38,42,43] and
151 standard tri-axial electrospinning [50], here we report the first modified tri-axial
152 electrospinning process. We have used this process to create core-shell fibers
153 comprising a lipid-drug core and a pH sensitive shell, thereby allowing us to
154 demonstrate that only an electrospinnable central fluid is required to achieve a
155 successful tri-axial process. The polymer-lipid nanocomposites produced showed
156 desirable functional performance in altering the release behavior of the model drug
157 diclofenac sodium and improving its permeation through the colonic membrane.

158 **2 Experimental**

159 **2.1. Materials**

160 Eudragit S100 (ES100, $M_w=135,000$), a methacrylic acid/methyl methacrylate
161 copolymer which only dissolves at $\text{pH} > 7.0$, was obtained from Röhm GmbH
162 (Darmstadt, Germany). Diclofenac sodium (DS, a non-steroidal anti-inflammatory
163 drug with potent anti-inflammatory, analgesic and antipyretic properties) was
164 purchased from the Hubei Biocause Pharmaceutical Co., Ltd. (Hubei, China).
165 Lecithin (PL, extracted from egg yolk, and containing lysophosphatidylcholine,
166 sphingomyelin, and neutral lipids in minor quantities), N,N-dimethylacetamide
167 (DMAc), anhydrous ethanol, methylene blue and basic fuchsin were purchased from
168 the Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). All other chemicals
169 used were analytical grade, and water was doubly distilled before use.

170 **2.2. Electrospinning**

171 The tri-layer concentric spinneret was homemade. Three syringe pumps
172 (KDS100, Cole-Parmer, Vernon Hills, IL, USA) and a high-voltage power supply
173 (ZGF 60kV/2 mA, Shanghai Sute Corp., Shanghai, China) were used for
174 electrospinning. The collector comprised a flat piece of cardboard wrapped with
175 aluminum foil. All electrospinning processes were carried out under ambient
176 conditions (21 ± 5 °C with a relative humidity of 47 ± 5 %). Experiments were
177 recorded using a digital camera (PowerShot A490, Canon, Tokyo, Japan). The
178 spinneret to collector distance was fixed at 15 cm for all experiments.

179 The outer fluid was pure anhydrous ethanol. The middle fluid consisted of 14.0 g

180 ES100 in 100 mL of a mixture of ethanol / DMAc (90:10 v/v). The inner fluid was
 181 prepared from 3 g PL and 0.6 g DS in 10 mL ethanol. After initial optimization
 182 experiments, the applied voltage was fixed at 15 kV. To facilitate observation of the
 183 electrospinning processes, 10 mg/L methylene blue was added to the inner fluid and 5
 184 mg/L basic fuchsin to the middle fluid. Four different sets of fibers were prepared
 185 with varied flow rates, as detailed in Table 1.

186

187 **Table 1.** Key details of the electrospinning processes and resultant fibers

No.	Process	F ₀ ^a (mL/h)	F _M ^a (mL/h)	F _I ^a (mL/h)	Morphology ^b	Diameter (μ m)
F1	Single	0	3.0	0	Linear	1.27 \pm 0.19
F2		0.5	2.0	0.5	Linear	0.55 \pm 0.06
F3	Tri-axial	0.5	1.6	0.9	Linear, with some beads	0.47 \pm 0.05
F4		1.0	1.6	0.4	Spindles-on-a-string	----

188

189

190

191

192

193

194

195

196

197 2.3. Characterization

198 2.3.1. Morphology

199 The morphology of the fibers was determined using a Quanta FEG450 field
 200 emission scanning electron microscope (FESEM; FEI Corporation, Hillsboro, OR,
 201 USA). Prior to examination, samples were gold sputter-coated under a nitrogen
 202 atmosphere to render them electrically conductive. Images were recorded at an
 203 excitation voltage of 20 kV. The average fiber size was determined by measuring their
 204 diameters at more than 100 places in FESEM images, using the NIH Image J software
 205 (National Institutes of Health, MD, USA). To view the cross-sections of sample F2, a
 206 section of the fiber mat was placed into liquid nitrogen and manually broken before

207 gold coating.

208 Transmission electron microscope (TEM) images of the samples were recorded
209 on a JEM 2100F field emission TEM (JEOL, Tokyo, Japan). Samples were collected
210 by fixing a lacey carbon-coated copper grid on the collector and electrospinning
211 directly onto it for several minutes.

212 2.3.2. *Physical form and compatibility*

213 X-ray diffraction (XRD) was conducted using a D/Max-BR diffractometer
214 (Rigaku, Tokyo, Japan) with Cu K α radiation over the 2θ range 5 to 60° at 40 kV and
215 30 mA. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR)
216 spectroscopy was carried out on a Nicolet-Nexus 670 FTIR spectrometer (Nicolet
217 Instrument Corporation, Madison, USA) from 500 cm⁻¹ to 4000 cm⁻¹ at a resolution
218 of 2 cm⁻¹.

219 2.3.3. *In vitro dissolution tests*

220 To determine drug loading efficiency (LE), 0.100 g of the fibers was added into
221 10 mL of a 10% v/v ethanol solution in water, in order to extract all the loaded DS.
222 The resultant solutions were diluted using phosphate buffered saline (PBS, pH7.0,
223 0.1M) to a suitable concentration for UV measurement. The LE was calculated using
224 the following equation:

$$225 \quad \text{LE(\%)} = (\text{DS mass measured})/(\text{theoretical DS mass in the formulation}) \times 100\%$$

226 *In vitro* dissolution tests were carried out according to the Chinese
227 Pharmacopoeia (2015 Ed.). Method II, which is a paddle method, was undertaken
228 using a RCZ-8A dissolution apparatus (Tianjin University Radio Factory, Tianjin,

229 China). 280 mg of fibers F2 or 20 mg of the DS raw material (particle size $<30 \mu\text{m}$)
230 were first placed in 600 mL of 0.1 M HCl. Two hours later, 2.4 g NaOH was added to
231 neutralize the dissolution media. The temperature of the dissolution medium was $37 \pm$
232 $1 \text{ }^\circ\text{C}$ and the instrument was stirred at 50 rpm. Sink conditions were maintained, with
233 $C < 0.2C_s$. At predetermined time points, 5.0 mL aliquots were withdrawn from the
234 dissolution medium and replaced with distilled water to maintain a constant volume.
235 After filtration through a $0.22 \mu\text{m}$ membrane (Millipore, Billerica, MA, USA) and
236 appropriate dilution with PBS, samples were analyzed at $\lambda_{\text{max}} = 276 \text{ nm}$ using a
237 UV-vis spectrophotometer (UV-2102PL, Unico Instrument Co. Ltd., Shanghai,
238 China). The cumulative amount of DS released at each time point was back-calculated
239 from the data obtained against a predetermined calibration curve. Experiments were
240 performed seven times, and the average results from six of these replicates are
241 reported as mean \pm S.D.

242 During the *in vitro* dissolution process, dissolution media from the seventh
243 replicate was withdrawn and the transmittance at $\lambda=500 \text{ nm}$ measured using the
244 UV-vis spectrophotometer. The average hydrodynamic diameter and size distribution
245 of the particles in the final dissolution medium from these experiments were
246 determined using a BI-200SM static and dynamic light scattering (SDLC) instrument
247 (Brookhaven Instruments Corporation, Austin, TX, USA).

248 2.3.4. *Ex vivo* permeation tests

249 *Ex vivo* permeation studies were performed using a RYJ-6A diffusion test
250 apparatus (Shanghai Huanghai Drug Control Instrument Co., Ltd., Shanghai, China),

251 in which materials were mounted in six Keshary-Chien glass diffusion cells and a
252 water bath system maintained a constant temperature of 37 ± 0.2 °C. Each cell had a
253 diffusion area of 2.60 cm^2 , and the receptor compartment had a capacity of 7.2 mL
254 PBS (pH7.0, 0.1M). Each donor compartment was filled with 1.0 mL PBS and the
255 hydrodynamics in the receptor compartment were maintained by stirring at 50 rpm
256 with a Teflon coated magnetic bead. Large intestines were obtained from pigs after
257 slaughtering (Baoshan Jiangwan slaughterhouse, Shanghai, China). The intestine was
258 washed carefully with physiological saline solution (NaCl 0.9% w/v) to remove
259 non-digested food. The colonic membranes were peeled away from the intestines and
260 fixed on diffusion cells with the mucosal walls upward. They were equilibrated at
261 35 °C for 30 min before permeation tests.

262 The F2 fibers (140 mg) were placed on the mucosal surface in the chambers.
263 Samples (1 mL) were withdrawn from the receptor compartment at timed intervals
264 and 1 mL fresh PBS was added to maintain the volume of fluid here at a constant
265 level. The aliquots were filtered through a $0.22 \mu\text{m}$ membrane (Millipore, Billerica,
266 MA, USA). The absorption of the filtrate was measured at 276 nm to determine the
267 amount of DS present in the aqueous phase. The semi-solid residue was dissolved
268 using 10 mL of a 10% v/v ethanol solution in water and diluted with PBS before
269 measuring absorbance, in order to determine its DS content of. All measurements
270 were carried out in triplicate. Permeation experiments with 10 mg of pure DS (particle
271 size $<30 \mu\text{m}$) as a control were also carried out.

272 2.4. Statistical analysis

273 The experimental data are presented as mean \pm SD. The results from the *in vitro*


274 dissolution tests and *ex vivo* permeation tests were analyzed using one-way ANOVA.
275 The threshold significance level was set at 0.05. Thus, *p* (probability) values lower
276 than 0.05 were considered statistically significant.

277 3. Results and discussion

278 3.1. Implementation of modified tri-axial electrospinning

279 A diagram illustrating the modified tri-axial electrospinning process is shown in
280 Fig. 1. The system consists of four components: three syringe pumps to drive the
281 working fluids, a power supply, a fiber collector, and a three layer concentric
282 spinneret. In modified coaxial electrospinning, the use of a spinnable core solution
283 can ensure a successful process regardless of the electrospinnability of the sheath fluid
284 [43]. Here, the central solution is electrospinnable, and this is utilized to achieve
285 tri-axial electrospinning even though the outer fluid is pure solvent and the inner fluid
286 is unspinnable.

287
288
289



300 The homemade tri-concentric spinneret and its connection with the power supply
301 and three working fluids are shown in Fig. 2a. An alligator clip was used to connect
302 the power supply to the spinneret, which was directly fixed to the syringe holding the

303 outer fluid. The middle and inner fluids were connected to the spinneret through
304 high-elastic silicon tubing.

305 The design of the spinneret is of critical importance in ensuring a robust and
306 reproducible electrospinning process [42,48]. A well-designed spinneret must provide
307 a suitable template for producing the desired nanofiber architectures, and must be
308 developed bearing in mind the behavior of the working fluids under an electrical field.
309 The spinneret used in this work is exhibited in the top-right and bottom-right insets of
310 Fig. 2a. It consists of three concentric capillaries composed of austenitic stainless steel
311 ($O_6Cr_{19}Ni_{10}$, GB24511 in China). The inner, middle and outer capillaries have outer
312 diameters of 0.4, 1.6, 2.8 mm and inner diameters (D_i) of 0.20, 1.3 and 2.2 mm,
313 respectively. The end of the inner capillary projects 0.2 mm out of the central one,
314 which similarly projects 0.2 mm from the outer capillary. This design helps to ensure
315 the encapsulation of the inner fluid by the middle fluid, and in turn the middle by the
316 outer fluid. This structure should also help to prevent mixing of the working fluids
317 when they are ejected from the spinneret.

318

319

320


321

322

323

324

325



326 **Fig. 2.** The implementation of modified tri-axial electrospinning: (a) the connection of
327 the spinneret with the power supply and the working fluids (left), and images of the
328 tri-concentric spinneret (insets); (b) a digital photograph of the tri-axial process (left),
329 the tri-layer droplet before a voltage of 15 kV was applied (top-right) and the
330 compound Taylor cone (bottom-right).

331

332 Under optimised conditions (see Section 2.2), successful electrospinning could
333 be achieved as shown in Fig. 2b. The process involves three steps including Taylor
334 cone formation, the emission of a straight fluid jet and then an unstable region with
335 gradually enlarged bending and whipping loops. The top-right inset of Fig. 2b
336 displays the droplets ejected from the spinneret with no voltage applied. Both the blue
337 inner fluid and pink middle fluids were observed to diffuse into the outer fluid to
338 some extent, as demonstrated by their gradually increased sizes and decreased size of
339 the outer (colourless) solvent moving away from the spinneret. However, the three
340 working fluids form a clear three-layer compound Taylor cone when a voltage of 15
341 kV was applied, as shown in the bottom-right inset of Fig. 2b.

342 The modified tri-axial electrospinning process can be run continuously and
343 smoothly, without any clogging or other adverse phenomena arising. These are
344 frequently encountered in traditional single-fluid and coaxial electrospinning [50], but
345 spinning with a pure solvent as the exterior fluid has been shown to reduce incidents
346 of clogging as well as to improve the uniformity of the fibers produced in the latter

347 process [42]. The use of pure solvent as the outer layer will: 1) lubricate the spinneret
348 to retard clinging; 2) prevent the formation of semi-solid substance on the surface of
349 the fluid jets; 3) protect the inner fluid from any environmental fluctuations; and, 4)
350 lead to a longer drawing period under the electrical field, and thus to narrower fibers.


351 *3.2. Morphology and core-shell structures of the created nanofibers*

352 FESEM images of fibers F1 to F4 are shown in Fig. 3. When the inner and
353 outer fluids were turned off, a traditional single-fluid electrospinning of the middle
354 ES100 solution could be achieved. Although manual intervention was needed
355 periodically to remove semi-solid substances which collected on the spinneret, the
356 resultant ES100 fibers were linear without any beads-on-a-string or
357 spindles-on-a-string morphology (Fig. 3a1 and 3a2). These fibers have an average
358 diameter of $1.27 \pm 0.13 \mu\text{m}$, with an uneven and wrinkled surface (Table 1, Fig. 3a2).
359 This is a result of barometric pressure, when residual solvent which was not
360 evaporated during electrospinning escaped from the fibers. Single-fluid
361 electrospinning easily traps solvent in the fibers because of the formation of a solid
362 “skin” on the fluid jet during the solidification process.

363 The F2 fibers are linear with an average diameter of $0.55 \pm 0.06 \mu\text{m}$ and smooth
364 surfaces (Fig. 3b1 and 3b2, Table 1). This can be attributed to the surrounding outer
365 solvent and appropriate selection of the flow rates of the three working fluids (0.5, 2.0
366 and 0.5 mL/h for outer, middle and inner fluids, respectively). If the flow rate of the
367 outer solvent is kept constant and those of the middle and inner fluid altered to 1.6
368 and 0.9 mL/h respectively, the resultant F3 material has many beads clinging to the

369 fibers, although the latter are still linear with an average size of $0.47 \pm 0.05 \mu\text{m}$ (Fig.
370 3b1 and 3b2, Table 1). It is thought that this high flow rate of the inner fluid causes it
371 to penetrate the middle and outer fluids to form round PL-DS beads on the fiber
372 surfaces.


373 If the flow rate of the outer solvent is doubled to 1.0 mL/h, the fibers generated
374 exhibit a typical spindles-on-a-string morphology (Fig. 3d1 and 3d2). Some
375 unexpected clumps are also formed within the fiber mat, as shown in the inset of Fig.
376 3d1. These are ascribed to PL escaping from the inner fluids. A further increase of the
377 outer solvent flow rate was found to result in an electrospaying process. These results
378 demonstrate that the selection of flow rates is a key parameter which must be
379 controlled to ensure the formation of a core-shell nanostructure.



389 **Fig. 3.** FESEM images of the core-shell nanofibers and their size distributions; (a1
390 and a2) F1; (b1 and b2) F2; (c1 and c2) F3; (d1 and d2) F4, the inset shows a clump
391 of PL-DS.

392

393 FESEM images of cross-sections of F2 (Fig. 4a) and TEM images (Fig. 4b)
394 demonstrate that the fibers have clear core/shell structures. Both the FESEM and
395 TEM images suggest that the PL-DS core has a diameter of approximately 300 nm.



400 **Fig. 4.** (a) A FESEM and (b) TEM image of the cross-sections of F2.

401

402 3.3. Physical form and component compatibility

403 XRD data are depicted in Fig. 5; these clearly demonstrate that DS is crystalline,
404 with many sharp Bragg reflections visible in its pattern. ES100 exhibits only a broad
405 hump, characteristic of an amorphous material. PL exists as a paste at an ambient
406 temperature of 21 °C, yet shows a sharp reflection at $2\theta=5.18^\circ$. This suggests that
407 there are liquid crystals present in the PL paste, with an ordered lamellar structure as
408 reported in the early literature [51]. All reflections from PL and DS are absent in the
409 patterns of the core-shell F2 fibers, suggesting the formation of an amorphous PL-DS
410 complex.

411

412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433




Fig. 5. XRD patterns of the raw materials (PL, EL100 and DS) and F2.

The potential secondary interactions between the fiber components were investigated using ATR-FTIR, and the results are shown in Fig. 6. DS has three characteristic peaks at 1574, 1553 and 1507 cm^{-1} arising from its benzene rings. In the spectrum of PL, the CH_2 symmetric and asymmetric vibrations at 2854 cm^{-1} and 2923 cm^{-1} and the antisymmetric stretch of $\text{N}^+(\text{CH}_3)_3$ at 968 cm^{-1} comprise the most prominent features. These peaks similarly appear in the spectrum of the fibers, confirming the presence of PL with ES100. However, the characteristic peaks from the benzene rings of DS cannot be seen in the F2 spectrum. This can be attributed to secondary interactions between PL and DS. Hydrophobic interactions, in addition to possible hydrogen bonding and electrostatic interactions, can arise between all three components in F2, as is clear from a consideration of the molecular structures in Fig. 6. These secondary interactions should ensure that the drug and excipients are highly compatible, favorable for the stability of the core-shell nanocomposites.


434

435

436

437

438



439 **Fig. 6.** ATR-FTIR spectra and the molecular formulae of the fiber components.

440


441 3.4. Functional performance

442 DS has a maximum absorbance at 276 nm, which was used to construct a
443 calibration curve: $A=0.0085+0.0279 C$ ($R=0.9997$) within a linear range from 2 to 50
444 $\mu\text{g/mL}$. The drug content in F2 was first assayed, and found to be $7.26 \pm 0.31\%$ ($n =$
445 6), almost identical to the calculated value of 7.14%.

446 The *in vitro* release profiles of F2 and the DS starting material are shown in Fig.
447 7a. DS is virtually insoluble in acidic conditions, with a small increase in solubility
448 when the pH is raised to neutral. After 2 h in acid, 2.8% of DS from the raw material
449 was freed into the dissolution media. When the pH was raised to neutral, the DS
450 particles gradually dissolved over *ca.* 3 hours. For F2, 2.1% of the loaded DS was
451 released during the first 2 h. In the neutral dissolution media, the nanofibers released a
452 total of 79.1% of the incorporated DS over 22 h.

453 ES100 is a pH-sensitive polymer, and is insoluble at pHs below 7.0; it can thus
454 be used to target DS to the colon region. DS is a popular API for oral administration
455 and is frequently used in the treatment of pain and peri-operatively. However, it can
456 easily result in an anaphylactic reaction, and to an allergic reaction in the digestive

457 tract [52,53]. With traditional electrospun nanofibers, the drug is released by diffusion
 458 through an insoluble polymeric matrix, or by an erosion mechanism from a
 459 water-soluble carrier (or a combination of both processes) [39,43]. Here the drug
 460 release from the core-shell composites is expected to include two successive steps
 461 (Fig. 7b). First, dissolution of the pH-sensitive ES100 shell will occur, with some
 462 diffusion of DS from the insoluble core PL. After dissolution of the shell ES100, the
 463 core PL-DS is not thought to be able to endure the shear forces of stirring applied
 464 during the experiment and thus we propose that the core is broken up into PL-DS
 465 particles. The DS is then gradually released from the resultant DS-PL aggregates.
 466 Thus in the dissolution tests, the released drug (%) corresponds to the DS molecules
 467 which are in solution (the DS-PL aggregates in suspension are removed by filtration).




476 **Fig. 7.** *In vitro* dissolution of DS and D2 (a) and the proposed drug release
 477 mechanism (b).

478
 479 To further investigate the drug release mechanism and validate this hypothesis,
 480 the transmittance of the dissolution media and light scattering studies were performed.
 481 The changes in transmittance at $\lambda=500$ nm are shown in Fig. 8a. DS has no
 482 absorbance above 320 nm, and thus any turbidity of the dissolution media recorded at
 483 this wavelength must result from the formation of a PL-DS suspension. In the first 2 h,

484 the transmittance remains virtually constant. After the pH is raised to neutral, the
485 transmittance values decreased for 3 h, after which they level out at around 77%. This
486 is consistent with the dissolution of the shell ES100 occurring over this period and
487 resulting in PL-DS nanoparticles.

488 The SDLC results obtained on the final dissolution medium are given in Fig. 8b.
489 The PL-DS particles formed have an average diameter of 434 nm with a
490 polydispersity index (PDI) of 0.187.




491
492
493
494
495
496

Fig. 8. (a) The transmittance of the dissolution medium measured at 500 nm as a function of time and (b) the sizes of the PL-DS particles measured by SDLC at the end of the dissolution experiment.

497 The results of permeation tests are presented in Fig. 9. DS is a Biopharmaceutical
498 class II drug, meaning it is poorly water-soluble but is able to effectively cross fatty
499 membranes [54]. After 12 h only 3.7 mg of the pure drug was transmitted into the
500 receptor cells. The dissolution of DS is very slow because there is only a very limited
501 amount of aqueous medium in the donor cell (*cf.* the dissolution experiments, which
502 are performed under sink conditions) [55]. For the F2 fibers, both dissolved DS and
503 the PL-DS particles penetrate the bio-membranes into the receptor cells [56].
504 Although the core-shell nanofibers provided sustained release of DS in dissolution
505 studies (much slower than the release from pure DS), after 12 h 8.1 ± 0.46 mg DS

506 from F2 had entered the receptor chamber. Of this amount, 1.7 ± 0.23 mg was present
507 in the aqueous phase (or in particles below 220 nm in size, which could pass through
508 the filters used). This suggests that $(8.1-1.7)/8.1 \times 100 = 79\%$ of the DS penetrated
509 through the mucosal membrane in the format of PL-DS particles. For oral
510 administration applications, this drug delivery route should alleviate any potential
511 allergic reactions with the digestive tracts.

512 Many commercial tablets are essentially a physical mixture of drug powders and
513 polymeric carrier, the latter being added to modulate the drug release behavior. The
514 combined use of polymer and lipid in the fibers prepared in the work is able to both
515 protect the API from release in the stomach and provide sustained release in the
516 colonic region, and also ensure improved trans-membrane permeability, leading to
517 more effective absorbance. This strategy is particularly useful for oral delivery of
518 Class IV drugs (which are both poorly water-soluble and have poor permeation
519 properties). Drug-loaded electrospun fibers can easily be converted into routine oral
520 solid dosage forms such as tablets and capsules using traditional pharmaceutical
521 protocols [57-59].



522
523
524

Fig. 9. *Ex vivo* permeation profiles of the F2 fibers and pure DS (n=6).

525 *3.5. Perspectives*

526 Coaxial electrospinning is often regarded as a major breakthrough in this field
527 [60,61]. The fact that only one of the working fluids needs to be electrospinnable for a
528 successful coaxial process significantly widens the range of materials which can be
529 processed, and a very broad family of core-shell nanostructures can be produced.
530 There are only about 100 polymers which can be directly electrospun into fibers, and
531 often these can only be processed within a narrow window of conditions
532 (concentration, voltage, etc). The introduction of unspinnable fluids in the modified
533 coaxial processes greatly expands the capability of this simple technology to produce
534 nanoscale products from a large range of raw materials. Furthermore, modified
535 coaxial electrospinning permits all types of liquid phase (including solvents, small
536 molecule solutions, dilute polymer solutions, suspensions and also emulsions) to be
537 processed.

538 In this work, we report the first example of modified tri-axial electrospinning.
539 Similar to modified co-axial spinning, this moves technology beyond the traditional
540 tri-axial process in which all three working fluids are required to be individually
541 electrospinnable. In our work, two of the three fluids were unspinnable alone: an
542 electrospinnable middle layer fluid is sufficient to ensure a successful tri-axial process.
543 This proof-of-concept work indicates that there are many possibilities in developing
544 functional nanofibers through the introduction of unspinnable outer-layer and
545 inner-layer working fluids into tri-axial processes.

546 The feasibility of the different tri-axial electrospinning processes which can be

547 conceived are summarized in Fig. 10. A process with three spinnable working fluids
 548 (Process I) has been reported in several publications [31,44,45]. Processes II, III and
 549 IV have two of the three fluids being electrospinnable, and these are feasible provided
 550 the working fluids are compatible. This report is an example of Process V, with a
 551 spinnable middle layer fluid used to support unspinnable outer and inner fluids. For
 552 processes VI and VII, the two unspinnable fluids are adjacent to each other. This may
 553 result in diffusion of the solutes and formation of a mixture of the two unspinnable
 554 liquids, and thus it is anticipated that such to tri-axial electrospinning processes will
 555 result in failure.

556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566

Process	Working fluid			Spinnable fluids	Feasibility	Fiber products	
	Inner	Middle	Outer				
Triaxial electrospinning	I				3	✓	
	II				2	✓	
	III				2	✓	
	IV				2	✓	
	V				1	✓	
	VI				1	✗	✗
	VII				1	✗	✗
Icon	Electro-spinnable	Un-spinnable	Feasible	None or infeasible	Tri-layer	Core-sheath	

567 **Fig. 10.** The feasibility of different tri-axial electrospinning processes.

568

569 4. Conclusions

570 A modified tri-axial electrospinning process was successfully implemented to create
 571 core-shell nanofibers, in which a spinnable Eudragit S100 (ES100) solution was used
 572 as the middle fluid to support the outer solvent and an unspinnable phosphatidyl
 573 choline (PL)/diclofenac sodium (DS) inner solution. This resulted in a continuous and
 574 trouble-free nanofabrication process. The resultant core-shell nanofibers have a linear

575 morphology with an obvious core-shell structure. XRD demonstrated that the
576 nanofibers are structural nanocomposites with both the drug DS and also the lipid
577 carrier PL losing their original crystalline physical forms and being transferred into an
578 amorphous state. These core (PL-DS)-shell (ES100) nanostructures can protect the
579 drug from release in acidic conditions to give colon-targeted release. They release the
580 drug through two successive steps at neutral pH: first, dissolution of the shell ES100
581 occurs, which is believed to generate PL-DS sub-micron sized particles. Subsequently,
582 release of DS from the particles occurs. The composite nanofibers lead to more than
583 twice as much drug permeation through the colonic bio-membrane when compared
584 with pure DS. The tri-axial electrospinning process developed in this work should
585 provide a new platform to fabricate structural nanomaterials, and polymer-PL
586 nanocomposites such as those prepared here can be utilized for effective oral drug
587 delivery.

588 **Acknowledgements**

589 This work was supported by the China NSFC/UK Royal Society cost share
590 international exchanges scheme (No. 51411130128/IE131748), the National Science
591 Foundation of China (Nos. 51373101 and 51373100), the Natural Science Foundation
592 of Shanghai (No. 13ZR1428900) and the Hujiang Foundation of China (No. B14006).
593 DP and LXX are also indebted to the Key Laboratory of Advanced Metal-based
594 Electrical Power Materials, Shanghai Municipal Commission of Education.

595 **References**

596 [1] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano
597 2009;3:16-20.

- 598 [2] Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug
599 delivery. *Adv Drug Del Rev* 2004;56:1621-1633.
- 600 [3] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering
601 biopharmaceuticals: formulation and delivery strategies. *Nat Rev Drug Discov*
602 2014;13:655-672.
- 603 [4] Sun J, Zhang L, Wang J, Feng Q, Liu D, Yin Q, Xu D, Wei Y, Ding B, Shi X,
604 Jiang X. Tunable rigidity of (polymeric core)–(lipid shell) nanoparticles for regulated
605 cellular uptake. *Adv Mater* 2015; 27:1402-1407.
- 606 [5] Liang X, Li J, Joo JB, Gutiérrez A, Tillekaratne A, Lee I, Yin Y, Zaera F.
607 Diffusion through the shells of yolk–shell and core–shell nanostructures in the liquid
608 phase. *Angew Chem Int Ed* 2012;51:8034-8036.
- 609 [6] Chen G, Xu Y, Yu DG, Zhang DF, Chatterton NP, White KN. Structure-tunable
610 Janus fibers fabricated using spinnerets with varying port angles. *Chem Commun*
611 2015;51:4623-3626.
- 612 [7] Bikiaris DN. Solid dispersions, Part II: new strategies in manufacturing methods
613 for dissolution rate enhancement of poorly water-soluble drugs. *Exp Opin Drug Del*
614 2011; 8:1663-1680.
- 615 [8] Eltayeb M, Stride E, Edirisinghe M. Electrospayed core-shell polymer-lipid
616 nanoparticles for active component delivery. *Nanotechnology* 2013;24:465604.
- 617 [9] Yu DG, Wang X, Li XY, Chian W, Li Y, Liao YZ. Electrospun biphasic drug
618 release polyvinylpyrrolidone/ ethyl cellulose core/sheath nanofibers, *Acta Biomater*
619 2013;9:5665-5672.
- 620 [10] Labbaf S, Deb S, Camma G, Stride E, Edirisinghe M. Preparation of
621 multi-component drug delivery nanoparticles using a triple-needle
622 electrohydrodynamic device. *J Colloid Interf Sci* 2013;409:245-254.
- 623 [11] Hubbell JA, Chikoti A. Nanomaterials for drug delivery. *Science*
624 2012;337:303-305.
- 625 [12] Perez RA, Kim HW. Core-shell designed scaffolds for drug delivery and tissue
626 engineering. *Acta Biomater* 2015; 21: 2-19.
- 627 [13] Yu DG, Yang JH, Wang X, Tian F. Liposomes self-assembled from
628 electrospayed composite microparticles. *Nanotechnology* 2012; 23:105606.
- 629 [14] Liu ZP, Cui L, Yu DG, Zhao ZX, Chen L. Electrospayed core-shell solid
630 dispersions of acyclovir fabricated using an epoxy-coated concentric spray head. *Int J*
631 *Nanomed* 2014;9:1967-1977.
- 632 [15] Yu DG, Williams GR, Yang JH, Wang X, Yang JM, Li XY. Solid lipid
633 nanoparticles self-assembled from electrospayed polymer-based micoparticles. *J*
634 *Mater Chem* 2011;21:15957-15961.

- 635 [16] Sun J, Xianyu Y, Jiang X. Point-of-care biochemical assays using gold
636 nanoparticle-implemented microfluidics. *Chem Soc Rev* 2014;43:6239-6253.
- 637 [17] Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as
638 a new generation therapeutic delivery platform: a review. *Eur J Pharm Biopharm*
639 2013;85:427-443.
- 640 [18] Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F,
641 Langer R, Farokhzad OC. Self-assembled lipid--polymer hybrid nanoparticles: a
642 robust drug delivery platform. *ACS Nano* 2008; 2:1696-1702.
- 643 [19] Qin CC, Duan XP, Wang L, Zhang LH, Yu M, Dong RH, Yan X, He HW, Long
644 YZ. Melt electrospinning of poly(lactic acid) and polycaprolactone microfibers by
645 using a hand-operated wimshurst generator. *Nanoscale* 2015;7:16611-16615.
- 646 [20] Jiang H, Wang L, Zhu K. Coaxial electrospinning for encapsulation and
647 controlled release of fragile water-soluble bioactive agents. *J Control Release*
648 2014;193: 296-303.
- 649 [21] Erickson AE, Edmondson D, Chang FC, Wood D, Gong A, Levengood SL,
650 Zhang M. High-throughput and high-yield fabrication of
651 uniaxially-aligned chitosan-based nanofibers by centrifugal electrospinning.
652 *Carbohydr Polym* 2015;134:467-474.
- 653 [22] Jiang K, Long YZ, Chen ZJ, Liu SL, Huang YY, Jiang X, Huang ZQ.
654 Airflow-directed in situ electrospinning of a medical glue of cyanoacrylate for rapid
655 hemostasis in liver resection. *Nanoscale* 2014;6:7792-7798.
- 656 [23] Sun B, Long YZ, Zhang HD, Li MM, Duvail JL, Jiang XY, Yin HL, Advances
657 in three-dimensional nanofibrous macrostructures via electrospinning. *Prog Polym Sci*
658 2014;39:862-890.
- 659 [24] Lu W, Sun J, Jiang X. Recent advances in electrospinning technology and
660 biomedical applications of electrospun fibers. *J Mater Chem B* 2014;2:2369-2380.
- 661 [25] Wang SW, Chen W, He S, Zhao QL, Li XH, Sun JS, Jiang XY.
662 Mesosilica-coated ultrafine fibers for highly efficient laccase encapsulation.
663 *Nanoscale* 2014;6: 6468-6472.
- 664 [26] Yu DG, White K, Chatterton NP, Li Y, Li L, Wang X. Structural lipid
665 nanoparticles self-assembled from electrospun core-shell polymeric nanocomposites.
666 *RSC Adv* 2015;5:9462-9466.
- 667 [27] Nagy ZK, Balogh A, Démuth B, Pataki H, Vigh T, Szabó B, Molnár K, Schmidt
668 BT, Horák P, Marosi G, Verreck G, Assche IV, Brewste ME. High speed
669 electrospinning for scaled-up production of amorphous solid dispersion of
670 itraconazole. *Int J Pharm* 2015;480:137-142.
- 671 [28] Kim SE, Wang J, Jordan AM, Shanda L, Korley TJ, Baer E, Pokorski JK.
672 Surface modification of melt extruded poly(ϵ -caprolactone) nanofibers: toward a new

673 scalable biomaterial scaffold. *ACS Macro Letters* 2014;3:585-589.

674 [29] Balogh A, Cselkó R, Démuth B, Verreck G, Mensch J, Marosi G, Nagy ZK.
675 Alternating current electrospinning for preparation of fibrous drug delivery systems.
676 *Int J Pharm* 2015;495:75-80.

677 [30] Qian W, Yu DG, Li Y, Liao YZ, Wang X, Wang L. Dual drug release electrospun
678 core-shell nanofibers with tunable dose in the second phase. *Int J Mol Sci*
679 2014;15:774-786.

680 [31] Yu DG, Li XY, Wang X, Yang JH, Annie Bligh SW, Williams GR. Nanofibers
681 fabricated using triaxial electrospinning as zero order drug delivery systems. *ACS*
682 *Appl Mater Interfaces* 2015;7:18891-18897.

683 [32] Chen H, Wang N, Di J, Zhao Y, Song Y, Jiang L. Nanowire-in-microtube
684 structured core/shell fibers via multifluidic coaxial electrospinning. *Langmuir* 2010;
685 26:11291-11296.

686 [33] Yarin AL. Coaxial electrospinning and emulsion electrospinning of core-shell
687 fibers. *Polym Adv Technol* 2011;22:310-317.

688 [34] Yarin AL, Zussman E, Wendorff JH, Greiner A. Material encapsulation and
689 transport in core-shell micro/nanofibers, polymer and carbon nanotubes and
690 micro/nanochannels. *J Mater Chem* 2007;17:2585-2599.

691 [35] Lee MW, An S, Lee C, Liou M, Yarin AL, Yoon SS. Hybrid self-healing matrix
692 using core-shell nanofibers and capsuleless microdroplets. *ACS Appl Mater Interfaces*
693 2014;6:10461-10468.

694 [36] Wang X, Zhang WJ, Yu DG, Li XY, Yang H. Epoxy resin nanofibers prepared
695 using electrospun core/sheath nanofibers as templates. *Macromol Mater Eng*
696 2013;298:664-669.

697 [37] Yu DG, Zhu LM, Branford-White C, Bligh SWA, White K. Coaxial
698 electrospinning with organic solvent for controlling the self-assembled nanoparticle
699 size. *Chem Commun* 2011;47:1216-1218.

700 [38] Agarwal S, Greiner A, Wendorff JH. Functional materials by electrospinning of
701 polymers. *Prog Polym Sci* 2013;38:963-991.

702 [39] Zhang Z, Liu S, Xiong H, Jing X, Xie Z, Chen X, Huang Y. Electrospun
703 PLA/MWCNTs composite nanofibers for combined chemo- and photothermal therapy.
704 *Acta Biomater* 2015; 26:115-123.

705 [40] Yu DG, Williams GR, Wang X, Liu XK, Li HL, Bligh SWA. Dual drug release
706 nanocomposites prepared using a combination of electrospinning and electrospinning.
707 *RSC Adv* 2013;3:4652-4658.

708 [41] Su Y, Su Q, Liu W, Lim M, Venugopal JR, Mo X, Ramakrishna S, Al-Deyab SS,
709 El-Newehy M. Controlled release of bone morphogenetic protein 2 and
710 dexamethasone loaded in core-shell PLLACL-collagen fibers for use in bone tissue

711 engineering. *Acta Biomater* 2012;8:763-771.

712 [42] Yu DG, Branford-White C, Bligh SWA, White K, Chatterton NP, Zhu LM
713 Improving polymer nanofiber quality using a modified co-axial electrospinning
714 process. *Macromol Rapid Commun* 2011;32:744-750.

715 [43] Yu DG, Chian W, Wang X, Li XY, Li Y, Liao YZ. Linear drug release membrane
716 prepared by a modified coaxial electrospinning process. *J Membrane Sci* 2013, 428,
717 150-156.

718 [44] Jiang S, Duan G, Zussman E, Greiner A, Agarwal S. Highly flexible and tough
719 concentric tri-axial polystyrene fibers. *ACS Appl Mater Interfaces* 2014;6:5918-5923.

720 [45] Liu W, Ni C, Chase DB, Rabolt JF. Preparation of multilayer biodegradable
721 nanofibers by tri-axial electrospinning. *ACS Macro Lett* 2013;2:466-468.

722 [46] Labbaf S, Ghanbar H, Stride E, Edirisinghe M. Preparation of multilayered
723 polymeric structures using a novel four-needle coaxial electrohydrodynamic device.
724 *Macromol Rapid Commun* 2014;35:618-623.

725 [47] Starr JD, Andrew JSA. Route to synthesize multifunctional tri-phase nanofibers.
726 *J Mater Chem C* 2013;1:2529-2533.

727 [48] Zhao Y, Cao X, Jiang L. Bio-mimic multichannel microtubes by a facile method.
728 *J Am Chem Soc* 2007;129:764-765.

729 [49] Han D, Steckl A. Triaxial electrospun nanofiber membranes for controlled dual
730 release of functional molecules. *ACS Appl Mater Interfaces* 2013;5:8241-8245.

731 [50] Illangakoon UE, Yu DG, Ahmad BS, Chatterton NP, Williams GR.
732 5-fluorouracil loaded Eudragit fibers prepared by electrospinning. *Int J Pharm*
733 2015;495:895-905.

734 [51] Small DM. Phase equilibria and structure of dry and hydrated egg
735 lecithin. *J Lipid Res* 1967;8:551-557.

736 [52] O'brien WM. Adverse reactions to nonsteroidal anti-inflammatory drugs.
737 Diclofenac compared with other nonsteroidal anti-inflammatory drugs. *Am J Med*
738 1986;80(4B): 70-80.

739 [53] Gibofsky A. Low-dose SoluMatrix diclofenac: a review of safety across two
740 phase III studies in patients with acute and osteoarthritis pain. *Expert Opin Drug Saf*
741 2015;25:1-13.

742 [54] Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for
743 poorly water-soluble drugs based on biopharmaceutics classification system: basic
744 approaches and practical applications. *Int J Pharm* 2011;420:1-10.

745 [55] Ritschel WA, Koch HP, Alcorn GJ. In vivo-in vitro correlations with
746 sustained-release theophylline preparations. *Methods Find Exp Clin Pharmacol*
747 1984;6:609-618.

- 748 [56]Kriwet K, Müller-Goymann CC, Diclofenac release from phospholipid drug
749 systems and permeation through excised human stratum corneum. *Int J Pharm* 1995;
750 125:231-242
- 751 [57]Hamori M, Yoshimatsu S, Hukuchi Y, Shimizu Y, Fukushima K, Sugioka N,
752 Nishimura A, Shibata N. Preparation and pharmaceutical evaluation of nano-fiber
753 matrix supported drug delivery system using the solvent-based electrospinning
754 method. *Int J Pharm* 2014; 464:243-251.
- 755 [58]Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and
756 characterization of nanofibers containing amorphous drug dispersions generated by
757 electrostatic spinning. *Pharm Res* 2003; 20:810-817.
- 758 [59]Démuth B, Nagy ZK, Balogh A, Vigh T, Marosi G, Verreck G, Assche IV,
759 Brewster ME. Downstream processing of polymer-based amorphous solid dispersions
760 to generate tablet formulations. *Int J Pharm* 2015;486:268-286.
- 761 [60] Dzenis Y. Spinning continuous fibers for nanotechnology. *Science*
762 2004;304:1917-1919.
- 763 [61] Chen CH, Chen SH, Shalumon KT, Chen JP. Dual functional core-sheath
764 electrospun hyaluronic acid/polycaprolactone nanofibrous membranes embedded with
765 silver nanoparticles for prevention of peritendinous adhesion. *Acta Biomater* 2015;
766 26:225-235.

767

768

769

770 **Table and Figures Legend**

771

772 **Table 1.** Key details of the electrospinning processes and resultant fibers

773 **Fig. 1.** A diagram of the modified tri-axial electrospinning process and its use for
774 preparing core-shell drug-loaded nanofibers.

775 **Fig. 2.** The implementation of modified tri-axial electrospinning: (a) the connection of
776 the spinneret with the power supply and the working fluids (left), and images of the
777 spinneret (insets); (b) a digital photograph of the tri-axial process (left), the droplet
778 before a voltage of 15 kV was applied (top-right) and the compound Taylor cone
779 (bottom-right).

780 **Fig. 3.** FESEM images of the core-shell nanofibers and their size distributions; (a1
781 and a2) F1; (b1 and b2) F2; (c1 and c2) F3; (d1 and d2) F4. The inset to (d1) shows a
782 clump of PL-DS.

783 **Fig. 4.** (a) A FESEM image of the cross-sections of F2 and (b) a TEM image showing
784 the same.

785 **Fig. 5.** XRD patterns of the raw materials (PL, EL100 and DS) and F2.

786 **Fig. 6.** ATR-FTIR spectra and the molecular formula of the fiber components.

787 **Fig. 7.** *In vitro* dissolution of DS and D2 (a) and the proposed drug release
788 mechanism (b).

789 **Fig. 8.** (a) The transmittance of the dissolution medium measured at 500 nm as a
790 function of time and (b) the sizes of the PL-DS particles measured by SDLC at the
791 end of the dissolution experiment.

792 **Fig. 9.** *Ex vivo* permeation profiles of the F2 fibers and pure DS (n=6). It should be
793 noted that it is not possible in the permeation experiment to distinguish between drug
794 in solution and in very small particles (< 220 nm) which could pass through the
795 filtration membrane used. Thus, some portion of the DS which had permeated in the
796 “free in water” experiment could in fact be in very small nanoparticles.

797 **Fig. 10.** The feasibility of different tri-axial electrospinning processes.

798